Business Context and Reporting Period
Company: BIO-RAD LABORATORIES, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2006
Business Overview: Bio-Rad is a multinational manufacturer and distributor of life science research and clinical diagnostics products. The company operates two primary segments: Life Science and Clinical Diagnostics. Approximately 64% of sales are international, creating exposure to currency fluctuations.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2006 |
Nine Months Ended Sep 30, 2006 |
|---|---|---|
| Net Sales | $304,764 | $930,849 |
| Gross Profit | $166,789 | $526,979 |
| Gross Margin | 54.7% | 56.6% |
| Net Income | $23,150 | $86,614 |
| Diluted EPS | $0.86 | $3.22 |
| Operating Cash Flow (9mo) | $63,366 | |
| Cash & Equivalents | $238,418 (as of Sep 30, 2006) | |
| Short-term Investments | $243,155 (as of Sep 30, 2006) | |
| Total Debt (Current + Long-term) | $429,518 (as of Sep 30, 2006) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 7.6% in the third quarter and 6.5% year-to-date compared to 2005. On a currency-neutral basis, sales grew 5.1% for the quarter and 7.7% for the nine-month period.
- Profitability: Net income rose 42.7% in the quarter and 27.2% year-to-date. The effective tax rate increased to 29% in the quarter (from 22% in 2005) and 27% year-to-date (from 24% in 2005), partly due to the adoption of SFAS 123(R).
- Segment Performance:
- Clinical Diagnostics: Sales grew 10.8% (quarter) and 10.8% (YTD). Growth was driven by blood virus, quality control products, and a $11.7 million settlement with bioMérieux.
- Life Science: Sales grew 4.0% (quarter) and 1.8% (YTD). Growth was offset by declining sales in the Bovine Spongiform Encephalopathy (BSE) product line.
- Unusual Items:
- Gain on Divestiture: A $4.7 million gain was recorded in "Other (income) expense, net" related to the exchange of Accent Semiconductor stock for Nanometrics stock and a facilitation fee.
- Litigation Settlement: Operating cash flows included a $45.96 million payment related to the MJ Research acquisition litigation settlement.
Guidance, Outlook, and Risks
- Acquisitions: The company announced the acquisition of Ciphergen Biosystems' ProteinChip Systems business for approximately $20 million and completed the acquisition of Blackhawk BioSystems for approximately $17 million in October 2006.
- Market Outlook: Management notes the diagnostic market is growing around 4% (currency neutral), while the life science market is growing about 5%. BSE test markets are declining due to consolidation and competition.
- Accounting Changes: The company adopted SFAS 123(R) effective January 1, 2006, recognizing share-based compensation expense. This reduced net income per share by $0.04 in the quarter and $0.13 year-to-date.
- Risks:
- Currency: Approximately 64% of sales are international; a strengthening US dollar negatively impacts reported sales.
- Legal: Ongoing patent litigation with Applera Corporation regarding real-time PCR technology in Europe. While a patent was reinstated in July 2006, it remains subject to review.
- Reimbursement: Pricing pressure in routine diagnostic tests due to declining government reimbursement schedules in the US, Japan, and Germany.
Investor Verification Checklist
- Currency Impact: Verify the extent to which reported sales growth is driven by currency fluctuations versus organic volume growth.
- BSE Product Line: Assess the trajectory of the declining BSE product line and its impact on the Life Science segment margins.
- Litigation Exposure: Monitor the status of the Applera patent dispute in Europe and potential impacts on sales in that region.
- Acquisition Integration: Review the financial impact and integration progress of the Ciphergen and Blackhawk acquisitions in subsequent filings.
- Share-Based Compensation: Confirm the ongoing impact of SFAS 123(R) on future earnings per share as unvested awards are amortized.